OM:EGTXBiotechs
Egetis Therapeutics (OM:EGTX) Heavy FY 2025 Losses Test Bullish Profitability Narratives
Egetis Therapeutics (OM:EGTX) FY 2025 Results in Focus
Egetis Therapeutics (OM:EGTX) has wrapped up FY 2025 with fourth quarter revenue of 17.9 million SEK and a basic EPS loss of 0.303213 SEK per share. This keeps the spotlight firmly on how efficiently it is funding its pipeline rather than on bottom line profits. The company’s revenue moved from 10.8 million SEK in Q4 2024 to 17.9 million SEK in Q4 2025, while trailing twelve month basic EPS sits at a loss of 0.930214 SEK alongside a...